Trial Profile
ATLAS-PPX: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in patients with hemophilia A and B previously receiving factor or bypassing agent prophylaxis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Fitusiran (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Registrational; Therapeutic Use
- Acronyms ATLAS-PPX
- Sponsors Alnylam Pharmaceuticals; Sanofi Genzyme; Sanofi K.K.
- 12 Dec 2023 Results of pooled analysis from Phase 1 (NCT02035605), Phase 1/2 (NCT02554773) and Phase 3 studies (NCT03417102, NCT03417245, NCT03549871) in PwH A/B, with or without inhibitors, PopPK/PD model, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 22 Sep 2023 This trial has been discontinued in Spain (Date of the global end of the trial: 25-Mar-2022), according to the European Clinical Trials Database record.
- 15 Jun 2023 Results (n=65) assessing CFC/BPA consumption with fitusiran prophylaxis vs CFC/BPA prophylaxis in PwHA/B, with or withoutinhibitorsassessing presented at the 28th Congress of the European Haematology Association